Pluvicto gets a no in Europe
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
Relay passes the baton to atirmociclib
The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
J&J’s second Halda asset goes clinical
An anti-ER “Riptac” enters phase 1.
Toxicity doesn't stop Incyte
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
Ominous signs for EGFR degraders
BeOne's degrader BG-60366 appears to have been discontinued.
Astra goes subcutaneous in its Merck race
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
Pfizer tries to banish the ghost of Celldex
A son of glembatumumab vedotin has just started its phase 1 study.
